[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)


Description

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combinati

Trial Eligibility

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score 0 to 2. * Participant has: * Fluorodeoxyglucose-positron emission tomography (FDG-PET) scan demonstrating positive lesion compatible with computed tomography (CT) or magnetic resonance image (MRI)-defined anatomical tumor sites AND * \>= 1 measurable nodal lesion (long axis \> 1.5 cm) or \>= 1 measurable extra-nodal lesion (long axis \> 1.0 cm) on CT scan or MRI. * Histologically confirmed classic follicular lymphoma (FL) \[previously Grade 1 to 3a FL\] stage II, III, or IV with no evidence of histologic transformation to an aggressive lymphoma and CD20+ disease on most recent representative tumor biopsy based on the pathology report. * Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy. (Participant who received only prior anti-CD20 mAb monotherapy and/or radiation therapy is not eligible.) * Eligible to receive R2 per investigator determination. * Estimated Creatinine Clearance (CrCl) \>= 50 mL/min. Exclusion Criteria: * Documented refractoriness to lenalidomide. * Have lenalidomide exposure within 12 months prior to randomization.

Study Info

Organization

Genmab


Primary Outcome

Progression-Free Survival (PFS)


Outcome Timeframe Up to approximately 5 years

NCTID NCT05409066

Phases PHASE3

Primary Purpose TREATMENT

Start Date 2022-09-20

Completion Date 2029-11-15

Enrollment Target 500

Interventions

DRUG Epcoritamab

DRUG Rituximab

DRUG Lenalidomide

Locations Recruiting

University of Arizona Cancer Center - North Campus /ID# 228862

United States, Arizona, Tucson


Alta Bates Summit Medical Center for Research /ID# 229428

United States, California, Berkeley


Long Beach Memorial Medical Ct /ID# 228997

United States, California, Long Beach


University of Southern California /ID# 227195

United States, California, Los Angeles


Emory University /ID# 227299

United States, Georgia, Atlanta


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Non-Hodgkin Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.